March 19, 2019

Vol. 16 No. 53

View Archived Issues

Sign Up Now

NCI Director Sharpless Named Acting FDA Director

Sharpless has advocated for increased modernization of clinical trials. Read More

FDA Green Lights New Generic Valsartan

Agency prioritized review to stave off shortages. Read More

Oklahoma AG Seeks J&J Docs in Opioid Lawsuit

J&J labeled “kingpin” of opioid crisis. Read More

Scotland Turns Down Kymriah Over Cost-Effectiveness

Evidence “not strong enough” to justify expense, regulator says. Read More

FDA Shares is Latest Thinking on Oncology Trial Eligibility

The series of draft guidances encourages a broadening of eligibility criteria. Read More